A July 6 Government Accountability Office (GAO) report examining Medicare Part B spending at hospitals participating in the 340B Drug Pricing Program draws unsubstantiated conclusions about a program that has a proven track record of improving access to care for poor patients and vulnerable communities. Simply put, the GAO report misses the mark.
AHA Stat Blog
Latest
A report paid for by a group backed by the pharmaceutical industry is the latest in a series of attempts to misrepresent a program that has a proven track record of helping poor patients and vulnerable communities.
A new report ;by the Berkley Research Group (BRG) is the latest attempt by the pharmaceutical industry to disparage a program with a proven track record of helping poor patients and vulnerable communities.
The 340B program accounts for only two percent of the $325 billion in annual drug purchases made in the U.S., or roughly $6.5 billion. Hospitals participating in the 340B program provided $28.4 billion in uncompensated care in 2012; in other words, four times the drug purchase amount.